Search

Your search keyword '"Figueroa J."' showing total 3,055 results
Start Over Author "Figueroa J."
3,055 results on '"Figueroa J."'

1. BIOINFORMATIC ANALYSIS OF GENOMIC ISLANDS IN WHOLE GENOMES OF PISCIRICKETTSIA SALMONIS STRAINS

Author

Soto-Rauch G., Nourdin-Galindo G., Haussmann D., and Figueroa J.

Subjects
геномный остров, геногруппа, piscirickettsia salmonis, штамм, патогенность, genomic islands, genogroup, strain, pathogenicity, Genetics, QH426-470
Abstract

Piscirickettsiosis, the cause of great losses in Chilean salmonid population, is produced by Piscirickettsia salmonis. The bacterium has developed resistance to treatments over time, including antibiotics and vaccines, due to a variety of evasive strategies, including biofilm formation. The bacterium has genomic islands, clusters of relevant genes that vary between genomes. This work aimed to analyze the relationship between number of pathogenic islands and their virulence genes in complete genomes from different strains of EM and LF genogroups, besides the search for genomic islands with non-virulent factors, like metabolic islands and fitness. Furthermore, we evaluated conservation and variation between strains from different genogroup, considering LF-89 (ATCC) and Psal-001 as reference strains, analyzing genomes through averages by two bioinformatic tools. About 13 pathogenic islands/strain were quantified, with 1 to 47 loci/island with unique behaviors for genogroup. Comparing islands regarding genomes, higher conservation rate was seen in EM genogroup, against oscillating values within LF genogroup strains. Non-virulent factors were also found. Overall, EM genogroup showed greater convergence in island conservation between strains concerning the pathogenic function compared to LF strains. Finally, different transposases were found to support high genomic plasticity and the scarcity of cured genes complicated correct identification.

Published
2023
Full Text
View/download PDF

6. Effects of a non-causal electromagnetic response on the linear momentum transfer from a swift electron to a metallic nanoparticle

Author

Castrejón-Figueroa, J., Castellanos-Reyes, J. Á., and Reyes-Coronado, A.

Subjects
Condensed Matter - Materials Science, Condensed Matter - Mesoscale and Nanoscale Physics
Abstract

Electron beams in Scanning Transmission Electron Microscopes (STEMs) can be used as a tool to induce movement on nanoparticles. Employing a classical-electrodynamics approach, it has been reported that the linear momentum transfer from a STEM-beam electron to a metallic spherical nanoparticle can be either repulsive or attractive towards the swift electron trajectory. This is in qualitative agreement with experimental observations. The interaction time between a swift electron and a nanoparticle is typically on the order of attoseconds. Hence, the electromagnetic response of the nanoparticle at short times is of utmost importance. However, it has been reported that the dielectric function employed in previous studies presented a non-causal pre-echo at the attosecond timescale, which might have lead to incorrect unphysical results. Therefore, the validity of these linear momentum transfer results should be revisited. In this theoretical work, we study the non-causality effects on the linear momentum transferred from a swift electron to a metallic nanoparticle, made of either aluminum or gold. Using an efficient numerical methodology, we found that non-causality, as well as deficient numerical convergence, may lead to incorrect repulsive linear momentum transfer results. Contrary to what previous theoretical studies have reported, our results show that the linear momentum transfer from a swift electron to spherical aluminum and gold nanoparticles, with radius 1 nm, is always attractive.

Published
2021
Full Text
View/download PDF

7. Time-dependent forces between a swift electron and a small nanoparticle within the dipole approximation

Author

Castrejón-Figueroa, J., Castellanos-Reyes, J. Á., Maciel-Escudero, C., Reyes-Coronado, A., and Barrera, R. G.

Subjects
Physics - Classical Physics
Abstract

In this paper we calculate the time-dependent forces between a swift electron traveling at constant velocity and a metallic nanoparticle made of either aluminum or gold. We consider that the nanoparticle responds as an electric point dipole and we use classical electrodynamics to calculate the force on both the nanoparticle and the electron. The values for the velocity of the electron and the radius of the nanoparticle were chosen in accordance with electron microscopy observations, and the impact parameter was selected to fulfill the constraints imposed by the dipole approximation. We found that there are times when the force on the nanoparticle is attractive and others when it is repulsive, and show that this is due to the delayed electromagnetic response of the nanoparticle. To establish the limits of validity of our approach, we calculate the total linear momentum transfer to the nanoparticle, and compare it with results obtained, in frequency space, using the full multipole expansion of the fields induced on the nanoparticle, considering the effects of electromagnetic radiation.

Published
2021
Full Text
View/download PDF

8. Enhanced spin injection in molecularly functionalized graphene via ultra-thin oxide barriers

Author

Toscano-Figueroa, J. C., Natera-Cordero, N., Bandurin, D. A., Anderson, C. R., Guarochico-Moreira, V. H., Grigorieva, I. V., and Vera-Marun, I. J.

Subjects
Condensed Matter - Mesoscale and Nanoscale Physics, Condensed Matter - Materials Science
Abstract

Realisation of practical spintronic devices relies on the ability to create and detect pure spin currents. In graphene-based spin valves this is usually achieved by injection of spin-polarized electrons from ferromagnetic contacts via a tunnel barrier, with Al2O3 and MgO used most widely as barrier materials. However, the requirement to make these barriers sufficiently thin often leads to pinholes and low contact resistances which in turn results in low spin injection efficiencies, typically 5% at room temperature, due to the so-called resistance mismatch problem. Here we demonstrate an alternative approach to fabricate ultra-thin tunnel barrier contacts to graphene. We show that laser-assisted chemical functionalization of graphene with sp3-bonded phenyl groups effectively provides a seed layer for growth of ultrathin Al2O3 films, ensuring smooth, high quality tunnel barriers and an enhanced spin injection efficiency. Importantly, the effect of functionalization on spin transport in the graphene channel itself is relatively weak, so that the enhanced spin injection dominates and leads to an order of magnitude increase in spin signals. Furthermore, spatial control of functionalization using a focused laser beam and lithographic techniques can in principle be used to limit functionalization to contact areas only, further reducing the effect on the graphene channel. Our results open a new route towards circumventing the resistance mismatch problem in graphene-based spintronic devices based on the easily available and highly stable Al2O3, and facilitate a step forward in the development of their practical applications., Comment: Manuscript: 11 pages, 3 figures. Supplemental material: 5 pages, 4 figures

Published
2021
Full Text
View/download PDF

9. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence

Author

Christ, Sebastian M., Youssef, Gilbert, Tanguturi, Shyam K., Cagney, Daniel, Shi, Diana, McFaline-Figueroa, J. Ricardo, Chukwueke, Ugonma, Lee, Eudocia Q., Hertler, Caroline, Andratschke, Nicolaus, Weller, Michael, Reardon, David A., Haas-Kogan, Daphne, Guckenberger, Matthias, Wen, Patrick Y., and Rahman, Rifaquat

Published
2024
Full Text
View/download PDF

10. When to update COVID-19 vaccine composition

Author

Grant, Rebecca, Sacks, Jilian A., Abraham, Priya, Chunsuttiwat, Supamit, Cohen, Cheryl, Figueroa, J. Peter, Fleming, Thomas, Fine, Paul, Goldblatt, David, Hasegawa, Hideki, MacIntrye, C. Raina, Memish, Ziad A., Miller, Elizabeth, Nishioka, Sergio, Sall, Amadou A., Sow, Samba, Tomori, Oyewale, Wang, Youchun, Van Kerkhove, Maria D., Wambo, Marie-Ange, Cohen, Homa Attar, Mesfin, Samuel, Otieno, James R., Subissi, Lorenzo, Briand, Sylvie, Wentworth, David E., and Subbarao, Kanta

Published
2023
Full Text
View/download PDF

22. A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).

Author

Nayak, Lakshmi, primary, Chukwueke, Ugonma Nnenna, additional, Meehan, Christopher, additional, Redd, Robert, additional, Hogan, Sarah, additional, Lee, Eudocia Quant, additional, Kim, Austin Injae, additional, Arrillaga-Romany, Isabel, additional, McFaline Figueroa, J. Ricardo Ricardo, additional, Gonzalez Castro, Luis Nicolas, additional, Murakami, Mark Alan, additional, Huang, Raymond Yi-kun, additional, Gerdemann, Ulrike, additional, Kaminski, James, additional, Filosto, Simone, additional, Poddar, Soumya, additional, Mattie, Mike, additional, Armand, Philippe, additional, Kean, Leslie, additional, and Jacobson, Caron Alyce, additional

Published
2024
Full Text
View/download PDF

25. Supplementary Table S3 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Author

Lim-Fat, Mary Jane, primary, Iorgulescu, J. Bryan, primary, Rahman, Rifaquat, primary, Bhave, Varun, primary, Muzikansky, Alona, primary, Woodward, Eleanor, primary, Whorral, Sydney, primary, Allen, Marie, primary, Touat, Mehdi, primary, Li, Xiaomei, primary, Xy, Gongwen, primary, Patel, Jay, primary, Gerstner, Elizabeth R., primary, Kalpathy-Cramer, Jayashree, primary, Youssef, Gilbert, primary, Chukwueke, Ugonma, primary, McFaline-Figueroa, J. Ricardo, primary, Nayak, Lakshmi, primary, Lee, Eudocia Q., primary, Reardon, David A., primary, Beroukhim, Rameen, primary, Huang, Raymond Y., primary, Bi, Wenya Linda, primary, Ligon, Keith L., primary, and Wen, Patrick Y., primary

Published
2024
Full Text
View/download PDF

26. Supplementary Figure S1 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Author

Lim-Fat, Mary Jane, primary, Iorgulescu, J. Bryan, primary, Rahman, Rifaquat, primary, Bhave, Varun, primary, Muzikansky, Alona, primary, Woodward, Eleanor, primary, Whorral, Sydney, primary, Allen, Marie, primary, Touat, Mehdi, primary, Li, Xiaomei, primary, Xy, Gongwen, primary, Patel, Jay, primary, Gerstner, Elizabeth R., primary, Kalpathy-Cramer, Jayashree, primary, Youssef, Gilbert, primary, Chukwueke, Ugonma, primary, McFaline-Figueroa, J. Ricardo, primary, Nayak, Lakshmi, primary, Lee, Eudocia Q., primary, Reardon, David A., primary, Beroukhim, Rameen, primary, Huang, Raymond Y., primary, Bi, Wenya Linda, primary, Ligon, Keith L., primary, and Wen, Patrick Y., primary

Published
2024
Full Text
View/download PDF

27. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Author

Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., and Arrese, M.

Subjects
Fatty liver -- Diagnosis -- Care and treatment, Cholic acid -- Testing, Eicosanoic acid -- Testing, Triglycerides -- Measurement, Nuclear magnetic resonance spectroscopy -- Usage, Liver cirrhosis -- Risk factors, Biological sciences, Health
Abstract

Nonalcoholic steatohepatitis (NASH), a chronic liver disease without an approved therapy, is associated with lipotoxicity and insulin resistance and is a major cause of cirrhosis and hepatocellular carcinoma. Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial. ARREST, a 52-week, double-blind, placebo-controlled, phase 2b trial randomized 247 patients with NASH (n = 101, n = 98 and n = 48 in the Aramchol 400 mg, 600 mg and placebo arms, respectively; NCT02279524). The primary end point was a decrease in hepatic triglycerides by magnetic resonance spectroscopy at 52 weeks with a dose of 600 mg of Aramchol. Key secondary end points included liver histology and alanine aminotransferase (ALT). Aramchol 600 mg produced a placebo-corrected decrease in liver triglycerides without meeting the prespecified significance (-3.1, 95% confidence interval (CI) -6.4 to 0.2, P = 0.066), precluding further formal statistical analysis. NASH resolution without worsening fibrosis was achieved in 16.7% (13 out of 78) of Aramchol 600 mg versus 5% (2 out of 40) of the placebo arm (odds ratio (OR) = 4.74, 95% CI = 0.99 to 22.7) and fibrosis improvement by [greater than or equal to]1 stage without worsening NASH in 29.5% versus 17.5% (OR = 1.88, 95% CI = 0.7 to 5.0), respectively. The placebo-corrected decrease in ALT for 600 mg was -29.1 IU l.sup.-1 (95% CI = -41.6 to -16.5). Early termination due to adverse events (AEs) was In a phase 2b study, inhibition of hepatic stearoyl-CoA desaturase in patients with nonalcoholic steatohepatitis was safe and tolerated; although reductions in liver fat were not significant, changes in liver enzymes and histology were observed., Author(s): V. Ratziu [sup.1] , L. de Guevara [sup.2] , R. Safadi [sup.3] , F. Poordad [sup.4] , F. Fuster [sup.5] , J. Flores-Figueroa [sup.6] , M. Arrese [sup.7] , [...]

Published
2021
Full Text
View/download PDF

28. Biotechnological Potential of Cottonseed, a By-Product of Cotton Production

Author

Rojo-Gutiérrez, E., Buenrostro-Figueroa, J. J., López-Martínez, L. X., Sepúlveda, D. R., Baeza-Jiménez, R., Jegatheesan, Jega V., Series Editor, Shu, Li, Series Editor, Lens, Piet, Series Editor, Chiemchaisri, Chart, Series Editor, Zakaria, Zainul Akmar, editor, Aguilar, Cristobal N, editor, Kusumaningtyas, Ratna Dewi, editor, and Binod, Parameswaran, editor

Published
2020
Full Text
View/download PDF

29. Considerations in boosting COVID-19 vaccine immune responses

Author

Krause, Philip R, Fleming, Thomas R, Peto, Richard, Longini, Ira M, Figueroa, J Peter, Sterne, Jonathan A C, Cravioto, Alejandro, Rees, Helen, Higgins, Julian P T, Boutron, Isabelle, Pan, Hongchao, Gruber, Marion F, Arora, Narendra, Kazi, Fatema, Gaspar, Rogerio, Swaminathan, Soumya, Ryan, Michael J, and Henao-Restrepo, Ana-Maria

Published
2021
Full Text
View/download PDF

30. Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic

Author

Hotez, Peter J., Batista, Carolina, Amor, Yanis Ben, Ergonul, Onder, Figueroa, J Peter, Gilbert, Sarah, Gursel, Mayda, Hassanain, Mazen, Kang, Gagandeep, Kaslow, David C., Kim, Jerome H., Lall, Bhavna, Larson, Heidi, Naniche, Denise, Sheahan, Timothy, Shoham, Shmuel, Wilder-Smith, Annelies, Sow, Samba O., Strub-Wourgaft, Nathalie, Yadav, Prashant, and Bottazzi, Maria Elena

Published
2021
Full Text
View/download PDF

31. Operation Warp Speed: implications for global vaccine security

Author

Kim, Jerome H, Hotez, Peter, Batista, Carolina, Ergonul, Onder, Figueroa, J Peter, Gilbert, Sarah, Gursel, Mayda, Hassanain, Mazen, Kang, Gagandeep, Lall, Bhavna, Larson, Heidi, Naniche, Denise, Sheahan, Timothy, Shoham, Shmuel, Wilder-Smith, Annelies, Strub-Wourgaft, Nathalie, Yadav, Prashant, and Bottazzi, Maria Elena

Published
2021
Full Text
View/download PDF

34. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence

Author

Christ, Sebastian M, Youssef, Gilbert, Tanguturi, Shyam K, Cagney, Daniel, Shi, Diana, McFaline-Figueroa, J Ricardo, Chukwueke, Ugonma, Lee, Eudocia Q, Hertler, Caroline, Andratschke, Nicolaus, Weller, Michael, Reardon, David A, Haas-Kogan, Daphne, Guckenberger, Matthias, Wen, Patrick Y, Rahman, Rifaquat, Christ, Sebastian M, Youssef, Gilbert, Tanguturi, Shyam K, Cagney, Daniel, Shi, Diana, McFaline-Figueroa, J Ricardo, Chukwueke, Ugonma, Lee, Eudocia Q, Hertler, Caroline, Andratschke, Nicolaus, Weller, Michael, Reardon, David A, Haas-Kogan, Daphne, Guckenberger, Matthias, Wen, Patrick Y, and Rahman, Rifaquat

Abstract

INTRODUCTION AND BACKGROUND While recurrent glioblastoma patients are often treated with re-irradiation, there is limited data on the use of re-irradiation in the setting of bevacizumab (BEV), temozolomide (TMZ) re-challenge, or immune checkpoint inhibition (ICI). We describe target delineation in patients with prior anti-angiogenic therapy, assess safety and efficacy of re-irradiation, and evaluate patterns of recurrence. MATERIALS AND METHODS Patients with a histologically confirmed diagnosis of glioblastoma treated at a single institution between 2013 and 2021 with re-irradiation were included. Tumor, treatment and clinical data were collected. Logistic and Cox regression analysis were used for statistical analysis. RESULTS One hundred and seventeen recurrent glioblastoma patients were identified, receiving 129 courses of re-irradiation. In 66 % (85/129) of cases, patients had prior BEV. In the 80 patients (62 %) with available re-irradiation plans, 20 (25 %) had all T2/FLAIR abnormality included in the gross tumor volume (GTV). Median overall survival (OS) for the cohort was 7.3 months, and median progression-free survival (PFS) was 3.6 months. Acute CTCAE grade ≥ 3 toxicity occurred in 8 % of cases. Concurrent use of TMZ or ICI was not associated with improved OS nor PFS. On multivariable analysis, higher KPS was significantly associated with longer OS (p < 0.01). On subgroup analysis, patients with prior BEV had significantly more marginal recurrences than those without (26 % vs. 13 %, p < 0.01). CONCLUSION Re-irradiation can be safely employed in recurrent glioblastoma patients. Marginal recurrence was more frequent in patients with prior BEV, suggesting a need to consider more inclusive treatment volumes incorporating T2/FLAIR abnormality.

Published
2024

37. A review of immunization legislation for children in English- and Dutch-speaking Caribbean countries/Revision de los marcos legislativos sobre vacunacion infantil en paises de habla inglesa y neerlandesa del Caribe/Revisao da legislacao relativa a imunizacao em criancas nos paises do Caribe de lingua inglesa e holandesa

Author

Evans-Gilbert, Tracy, Lewis-Bell, Karen N., Irons, Beryl, Duclos, Philippe, Gonzalez-Escobar, Gabriel, Ferdinand, Elizabeth, and Figueroa, J. Peter

Published
2023
Full Text
View/download PDF

41. Establishing priorities to strengthen National Immunization Technical Advisory Groups in Latin America and the Caribbean

Author

Evans-Gilbert, Tracy, primary, Figueroa, J. Peter, additional, Bonvehí, Pablo, additional, Melgar, Mario, additional, Stecher, Daniel, additional, Kfouri, Renato, additional, Munoz, Greta, additional, Bansie, Rakesh, additional, Valenzuela, Renato, additional, Verne, Eduardo, additional, Salas, Daniel, additional, and Jennifer Sanwogou, N., additional

Published
2024
Full Text
View/download PDF

43. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Author

Lim-Fat, Mary Jane, primary, Iorgulescu, J. Bryan, additional, Rahman, Rifaquat, additional, Bhave, Varun, additional, Muzikansky, Alona, additional, Woodward, Eleanor, additional, Whorral, Sydney, additional, Allen, Marie, additional, Touat, Mehdi, additional, Li, Xiaomei, additional, Xy, Gongwen, additional, Patel, Jay, additional, Gerstner, Elizabeth R., additional, Kalpathy-Cramer, Jayashree, additional, Youssef, Gilbert, additional, Chukwueke, Ugonma, additional, McFaline-Figueroa, J. Ricardo, additional, Nayak, Lakshmi, additional, Lee, Eudocia Q., additional, Reardon, David A., additional, Beroukhim, Rameen, additional, Huang, Raymond Y., additional, Bi, Wenya Linda, additional, Ligon, Keith L., additional, and Wen, Patrick Y., additional

Published
2024
Full Text
View/download PDF

44. Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium

Author

Lei, J, Rudolph, A, Moysich, KB, Behrens, S, Goode, EL, Bolla, MK, Dennis, J, Dunning, AM, Easton, DF, Wang, Q, Benitez, J, Hopper, JL, Southey, MC, Schmidt, MK, Broeks, A, Fasching, PA, Haeberle, L, Peto, J, dos-Santos-Silva, I, Sawyer, EJ, Tomlinson, I, Burwinkel, B, Marmé, F, Guénel, P, Truong, T, Bojesen, SE, Flyger, H, Nielsen, SF, Nordestgaard, BG, González-Neira, A, Menéndez, P, Anton-Culver, H, Neuhausen, SL, Brenner, H, Arndt, V, Meindl, A, Schmutzler, RK, Brauch, H, Hamann, U, Nevanlinna, H, Fagerholm, R, Dörk, T, Bogdanova, NV, Mannermaa, A, Hartikainen, JM, Australian Ovarian Study Group, kConFab Investigators, Van Dijck, L, Smeets, A, Flesch-Janys, D, Eilber, U, Radice, P, Peterlongo, P, Couch, FJ, Hallberg, E, Giles, GG, Milne, RL, Haiman, CA, Schumacher, F, Simard, J, Goldberg, MS, Kristensen, V, Borresen-Dale, AL, Zheng, W, Beeghly-Fadiel, A, Winqvist, R, Grip, M, Andrulis, IL, Glendon, G, García-Closas, M, Figueroa, J, Czene, K, Brand, JS, Darabi, H, Eriksson, M, Hall, P, Li, J, Cox, A, Cross, SS, Pharoah, PDP, Shah, M, Kabisch, M, Torres, D, Jakubowska, A, Lubinski, J, Ademuyiwa, F, Ambrosone, CB, Swerdlow, A, Jones, M, and Chang-Claude, J

Subjects
Genetics, Complementary and Alternative Medicine, Paediatrics and Reproductive Medicine, Genetics & Heredity
Abstract

Immunosuppression plays a pivotal role in assisting tumors to evade immune destruction and promoting tumor development. We hypothesized that genetic variation in the immunosuppression pathway genes may be implicated in breast cancer tumorigenesis. We included 42,510 female breast cancer cases and 40,577 controls of European ancestry from 37 studies in the Breast Cancer Association Consortium (2015) with available genotype data for 3595 single nucleotide polymorphisms (SNPs) in 133 candidate genes. Associations between genotyped SNPs and overall breast cancer risk, and secondarily according to estrogen receptor (ER) status, were assessed using multiple logistic regression models. Gene-level associations were assessed based on principal component analysis. Gene expression analyses were conducted using RNA sequencing level 3 data from The Cancer Genome Atlas for 989 breast tumor samples and 113 matched normal tissue samples. SNP rs1905339 (A>G) in the STAT3 region was associated with an increased breast cancer risk (per allele odds ratio 1.05, 95 % confidence interval 1.03–1.08; p value = 1.4 × 10−6). The association did not differ significantly by ER status. On the gene level, in addition to TGFBR2 and CCND1, IL5 and GM-CSF showed the strongest associations with overall breast cancer risk (p value = 1.0 × 10−3 and 7.0 × 10−3, respectively). Furthermore, STAT3 and IL5 but not GM-CSF were differentially expressed between breast tumor tissue and normal tissue (p value = 2.5 × 10−3, 4.5 × 10−4 and 0.63, respectively). Our data provide evidence that the immunosuppression pathway genes STAT3,IL5, and GM-CSF may be novel susceptibility loci for breast cancer in women of European ancestry.

Published
2016

45. Mechanisms and therapeutic implications of hypermutation in gliomas

Author

Touat, Mehdi, Li, Yvonne Y., Boynton, Adam N., Spurr, Liam F., Iorgulescu, J. Bryan, Bohrson, Craig L., Cortes-Ciriano, Isidro, Birzu, Cristina, Geduldig, Jack E., Pelton, Kristine, Lim-Fat, Mary Jane, Pal, Sangita, Ferrer-Luna, Ruben, Ramkissoon, Shakti H., Dubois, Frank, Bellamy, Charlotte, Currimjee, Naomi, Bonardi, Juliana, Qian, Kenin, Ho, Patricia, Malinowski, Seth, Taquet, Leon, Jones, Robert E., Shetty, Aniket, Chow, Kin-Hoe, Sharaf, Radwa, Pavlick, Dean, Albacker, Lee A., Younan, Nadia, Baldini, Capucine, Verreault, Maïté, Giry, Marine, Guillerm, Erell, Ammari, Samy, Beuvon, Frédéric, Mokhtari, Karima, Alentorn, Agusti, Dehais, Caroline, Houillier, Caroline, Laigle-Donadey, Florence, Psimaras, Dimitri, Lee, Eudocia Q., Nayak, Lakshmi, McFaline-Figueroa, J. Ricardo, Carpentier, Alexandre, Cornu, Philippe, Capelle, Laurent, Mathon, Bertrand, Barnholtz-Sloan, Jill S., Chakravarti, Arnab, Bi, Wenya Linda, Chiocca, E. Antonio, Fehnel, Katie Pricola, Alexandrescu, Sanda, Chi, Susan N., Haas-Kogan, Daphne, Batchelor, Tracy T., Frampton, Garrett M., Alexander, Brian M., Huang, Raymond Y., Ligon, Azra H., Coulet, Florence, Delattre, Jean-Yves, Hoang-Xuan, Khê, Meredith, David M., Santagata, Sandro, Duval, Alex, Sanson, Marc, Cherniack, Andrew D., Wen, Patrick Y., Reardon, David A., Marabelle, Aurélien, Park, Peter J., Idbaih, Ahmed, Beroukhim, Rameen, Bandopadhayay, Pratiti, Bielle, Franck, and Ligon, Keith L.

Published
2020
Full Text
View/download PDF

49. EL SECTOR FITNESS AL INTERIOR DE MÉXICO PARA 2024: ANÁLISIS DESDE SUS DISTINTAS REGIONES.

Author

Gómez Chávez, L. F. J., Gómez-Figueroa, J. A., Cortés-Almanzar, P., López Haro, J., Pelayo Zavalza, A. R., Meza-Segura, R., Ontiveros-Hernández, Z., and Aguirre Rodríguez, L. E.

Abstract

Copyright of Revista Iberoamericana de Ciencias de la Actividad Física y el Deporte is the property of Revista Iberoamericana de Ciencias de la Actividad Física y el Deporte and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results